Development of biomarker predicting the response of immunotherapy for patients with urothelial cancer using urine miRNA

Development of biomarker predicting the response of immunotherapy for patients with urothelial cancer using urine miRNA - Development of precision medicine for patients with urothelial cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047198

Enrollment

120

Registered

2022-03-18

Start date

2022-03-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

urothelial cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Male or female patients 20 years of age or older on the date of the consent 2.Documented histological or radiological diagnosis of urothelial carcinoma without metastasis and without patients after radical cystectomy 3.Voluntary written consent must be given after sufficient explanation with the understanding what this study is and that consent may be withdrawn by the patient at any time without prejudice to future medical care

Exclusion criteria

Exclusion criteria: 1, patients with history of using immunotherapy for urothelial or non-urothelial carcinoma before the registration of this study. 2, patients with other cancer

Design outcomes

Primary

Measure	Time frame
The difference of the urine miRNAs between patients with good and poor response for immunotherapy will be analyzed for patients with urothelial cancer before immunotherapy.	—

Countries

Japan

Contacts

Public ContactYosuke Hirasawa

Tokyo Medical University Department of Urology

wbqmd473@yahoo.co.jp0333426111

Outcome results